{"id":"W2621772424","doi":"10.1200/jco.2017.35.15_suppl.tps1114","title":"A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Fulvestrant; Medicine; Bromodomain; Tolerability; Estrogen receptor; Pharmacodynamics; Breast cancer; Pharmacology; Metastatic breast cancer; Estrogen; Oncology; BRD4; Cancer; Pharmacokinetics; Internal medicine; Cancer research; Adverse effect; Histone; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001861745,0.002075653,0.002490397,0.0008104985,0.0004473672,0.0009997197,0.001141294,0.001834649,0.006850201],"category_scores_gemma":[0.0009511145,0.0007377593,0.001250333,0.0006878659,0.001362048,0.001332079,0.0004247287,0.004084397,0.001731024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001137211,"about_ca_system_score_gemma":0.001771071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001062881,"about_ca_topic_score_gemma":0.001915351,"domain_scores_codex":[0.9994878,0.0001909717,0.000020991,0.0001013998,0.00005589517,0.0001429776],"domain_scores_gemma":[0.9991183,0.0001038259,0.0001742695,0.0001221362,0.0000677826,0.0004137037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5860776,0.1945502,0.003955499,0.000893541,0.0007922455,0.0003437392,0.0003204598,0.003012457,0.1109983,0.0004882566,0.006657334,0.09191028],"study_design_scores_gemma":[0.4015585,0.5838111,0.005374153,0.00002459449,0.0002121878,0.000218891,0.0000529434,0.0007972079,0.005023689,0.0002231116,0.002676085,0.00002763894],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9812545,0.001819668,0.001379566,0.0008639774,0.0002030133,0.009592849,0.002128009,0.0002458329,0.002512499],"genre_scores_gemma":[0.965843,0.002151127,0.004715764,0.002247026,0.0002297933,0.01233759,0.005177323,0.00008779669,0.007210551],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006850201,"threshold_uncertainty_score":0.02291626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05238871350406102,"score_gpt":0.4423437751726905,"score_spread":0.3899550616686295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}